The oral RAS(ON) inhibitor from Revolution Medicines beat standard chemotherapy on overall survival in a randomized Phase 3, the first OS win for the class, and a result that raises the bar for every KRAS program still in development.
Pancreatic cancer kills roughly 90% of patients diagnosed with it. The KRAS gene is mutated in about 90% of those tumors. For four decades, that combination made it oncology's most stubborn target: a driver gene, clearly causal, with no drug that could reliably turn it off. Standard chemotherapy extended life by a few months at best. Then on April 13, 2026, Revolution Medicines reported that its once-daily pill daraxonrasib beat that chemotherapy on overall survival in a randomized Phase 3 trial of patients with previously treated metastatic disease. It is the first time a RAS-targeted drug has done so at a registrational stage.
The topline numbers, from the company's press release, are the largest seen in a randomized Phase 3 for this disease. Median overall survival reached 13.2 months on daraxonrasib versus 6.7 months on standard IV cytotoxic chemotherapy. The hazard ratio was 0.40, a 60% reduction in the risk of death, with a p-value below 0.0001 in the intent-to-treat population. Progression-free survival and overall survival were co-primary endpoints, and both were met. The company called the readout a first interim analysis with endpoints considered final.
These are topline figures from a single sponsor. Full data, including subgroup analyses, durability beyond the median, and the full safety picture, will come at ASCO 2026 and in a planned New Drug Application to the FDA. Revolution Medicines said it intends to file the NDA using a Commissioner's National Priority Voucher, a regulatory tool that compresses review timelines for therapies the agency has flagged as addressing urgent unmet need. The choice is a business signal as much as a regulatory one: the company is spending a finite, tradeable asset on this filing, which means it is betting the underlying data will hold up to inspection.
The mechanism is what oncologists have been waiting to see validated at this scale. Daraxonrasib is what Revolution Medicines calls a RAS(ON) tri-complex inhibitor and what investigators at Memorial Sloan Kettering and Dana-Farber describe, more accessibly, as a molecular glue. The drug binds to RAS proteins while they are in their active, growth-signaling state, then recruits a chaperone protein that traps them there. Existing KRAS inhibitors, by contrast, mostly hit the inactive state and only work in a narrow G12C subset of pancreatic cancer patients. The Pancreatic Cancer Action Network frames daraxonrasib as the first RAS inhibitor to extend survival in previously treated metastatic disease, a first-in-class designation that goes to status, not to final verdict.
Brian Wolpin at Dana-Farber, principal investigator for the Phase 3 RASolute 302 trial, previously reported early efficacy signals from the molecule through Dana-Farber's newsroom. That earlier work showed durable responses across KRAS mutation subtypes, not just G12C. The Phase 3 win gives the broader RAS(ON) class its first randomized survival benchmark. DrugHunter named daraxonrasib its 2025 Molecule of the Year on the strength of that earlier data, the kind of industry recognition that signals which compounds the drug-discovery community is watching most closely. The structural work behind the tri-complex mechanism was published in Nature Scientific Reports.
The mainstream press has caught up. A Washington Post explainer from May 24, 2026 framed the result as the moment "undruggable" stopped being the right word for KRAS. That framing is a stretch. The median survival gain of 6.5 months is the largest seen in a randomized Phase 3 for this disease, but it is not a cure. Roughly 90% of pancreatic cancer patients still die of their disease, and the long tail of the survival curve is not yet known. What the result does change is the playing field for the next generation of RAS programs.
Three things to watch next. First, ASCO 2026: full hazard ratios, subgroup analyses, and durability data beyond the median will tell oncologists how to position daraxonrasib in their sequencing decisions. Second, the NDA: a successful filing accelerated by a Priority Voucher would compress the typical FDA review timeline and set a template for future RAS programs. Third, the competition. Amgen's sotorasib and Mirati's adagrasib already hold accelerated approvals in KRAS G12C lung cancer, a smaller and biologically different population. Bristol Myers Squibb's MRTX1133, a G12D-targeted agent now in early trials, was designed for the same pancreatic population daraxonrasib just won. A randomized OS win for the broader RAS(ON) class raises the bar for every program still in development and reframes what counts as a competitive threshold.
For oncologists treating metastatic pancreatic cancer today, the practical question is sequencing. The current standard for previously treated patients is chemotherapy, usually liposomal irinotecan combinations. If the Phase 3 data hold up to peer review, daraxonrasib becomes the new benchmark for that line of therapy. The next round of clinical trials will be designed around it, either as a backbone for combinations with immunotherapy or chemotherapy, or as the comparator arm for whatever comes next.
The press release is a single sponsor's announcement. Full data are coming. What arrives will determine whether this is a durable new option or a strong first step in a class that still has work to do.